Drug Trial Radar · NCT06502964
Study of ALTO-101 in Patients With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Jun 11, 2024
Primary completion
Feb 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- Alto NeuroscienceIndustry
- Sponsor type
- Industry
- First posted
- Jul 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.
Conditions
- Schizophrenia
- Cognitive Impairment
Interventions
ALTO-101Drug
ALTO-101 patches
ALTO-101 Transdermal Delivery SystemDevice
ALTO-101 transdermal delivery system
PlaceboDrug
Inactive placebo patches
Placebo Transdermal Delivery SystemDevice
Placebo transdermal delivery system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Theta band activityTime frame: Treatment Period 1 - Day 6 and Day 11; Treatment Period 2 - Day 6 and Day 11
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Site 5038
Garden Grove, California · Recruiting
Site 5063
Los Angeles, California · Recruiting
Site 5106
Orange, California · Recruiting
Site 5035
Walnut Creek, California · Recruiting
Site 5060
Hollywood, Florida · Recruiting
Site 5015
Tampa, Florida · Recruiting
Site 5064
Snellville, Georgia · Recruiting
Site 5056
Chicago, Illinois · Recruiting
Site 5062
Gaithersburg, Maryland · Recruiting
Site 5124
Belmont, Massachusetts · Recruiting
Site 5108
New York, New York · Recruiting
Site 5077
New York, New York · Recruiting
Site 5109
New York, New York · Withdrawn
Site 5126
White Plains, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.